New Analysis Demonstrates UPLIZNA® (inebilizumab-cdon) Reduces Severity of Attacks Associated with Neuromyelitis Optica Spectrum Disorder (NMOSD)

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc announced results from an analysis showing treatment with UPLIZNA effectively reduced the severity of attacks in NMOSD.